Title
Category
Credits
Event date
Cost
Advanced Education Certification Series: Cannabinoids
  • PAINWeek
  • 11.00 AANP
  • 11.00 ACCME (All Other)
  • 11.00 ACCME (MD/DO Only)
  • 11.00 ACPE Pharmacy
  • 11.00 ANCC
  • 11.00 APA
$1,500.00
Advanced Education Certification Series: Opioids
  • 15.25 AANP
  • 15.25 ACCME (All Other)
  • 15.25 ACCME (MD/DO Only)
  • 15.25 ACPE Pharmacy
  • 15.25 ANCC
  • 15.00 APA
$1,500.00
Advanced Education Certification Series: Palliative Care
  • PAINWeek
  • 20.00 AANP
  • 20.00 ACCME (All Other)
  • 20.00 ACCME (MD/DO Only)
  • 20.00 ACPE Pharmacy
  • 20.00 ANCC
  • 20.00 APA
$1,500.00
Clinical Brief: Prevention and Treatment of Influenza in High-Risk Patients with Cardiometabolic Comorbidities
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Gregory Poland, the symposium reviewed the latest literature on the epidemiology, prevention, diagnosis, and treatment for influenza. The panel also highlighted the connection between influenza and other diseases, particularly its impact on cardiovascular diseases. There was an emphasis on the aspects that health care providers should focus on when treating patients with influenza.
Clinical Brief: Challenges and Advances in Diabetic Kidney Disease
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
This enduring clinical brief was developed from a primetime symposium at the 2021 CMHC Annual Congress. Moderated by Dr. Bakris, the symposium highlighted the importance of and the challenges in managing renal disease in patients with diabetes. The panel also gave a thorough background on the development of a non-steroidal mineralocorticoid receptor antagonist, a new drug class that shows promising results in tackling inflammation and fibrosis in patients with diabetes and renal disease.
Case Study - Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
$0.00
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Despite advances in therapy, many patients with DKD progress to kidney failure and have significant cardiovascular adverse events, and current strategies to address cardiorenal risk in these patients are inadequate.
CMHC Spring 2022 On Demand
  • CMHC
  • 16.25 ACPE Pharmacy
  • 16.25 AMA PRA Category 1 Credit™
  • 16.25 ANCC
  • 16.25 CDE
  • 16.25 Participation
$0.00
The 2022 CMHC Spring recorded sessions highlight the latest updates in CKD, heart failure, hypertension, type 2 diabetes, dyslipidemia, lifestyle management, obesity, and cardiovascular health, as well as translate cutting-edge medical research into practical, clinical strategies for preventing, delaying, and managing cardio-renal-metabolic disorders.
CMHC Masterclass On Demand: Connecting the Dots in Cardiometabolic Medicine - Integrative Approaches to Improve Patient Care
  • CMHC
  • 14.00 ACPE Pharmacy
  • 14.00 AMA PRA Category 1 Credit™
  • 14.00 ANCC
  • 14.00 CDE
  • 14.00 Participation
$0.00
Utilizing thought-provoking and interactive discussions, multidisciplinary experts in this masterclass cover advances in lifestyle, nutrition, genetics, and pharmacotherapy to prevent and address obesity, cardiovascular disease, hypertension, dyslipidemia, type 2 diabetes, kidney disease and more. Each section will include expert panel discussions, which will aim to provide practical approaches to patient management and interpret the latest advances to patient care.
The Staying Power of Immunotherapies: Approaching Melanoma Care from an Inclusive Perspective
  • LivDerm
  • TME
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Melanoma can be a life-threatening condition if left untreated. Patients with skin of color often face delays in diagnosis and treatment initiation in melanoma care. These disparities point to the need for increased awareness and education on melanoma risk and identification for clinicians and patients. Immunotherapies as mono and combination therapeutic regimens have become the gold standard in melanoma management.
Virtual Symposium: CGM - Going Beyond HbA1c to Optimize and Individualize T2D Management
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
$0.00
Measuring HbA1c has been the method of choice to assess glucose control; however, it does not reflect potential glucose excursions leading to hypoglycemia or postprandial hyperglycemia, which increase the risk of long-term complications, as well as overall glycemic variability. Continuous glucose monitoring (CGM) technology can circumvent some of these issues in T2DM management by providing near real-time glucose concentrations derived from interstitial fluid; and studies with CGM have demonstrated its efficacy and safety in this setting.

Pages